{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:04:26Z","timestamp":1791331466360,"version":"4.3.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"1156","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Young Talent Program of China National Nuclear Corporation","award":["CNNC2021137"],"award-info":[{"award-number":["CNNC2021137"]}]},{"name":"Sichuan Science and Technology Innovation and Entrepreneurship Seedling","award":["2021JDRC0170"],"award-info":[{"award-number":["2021JDRC0170"]}]},{"name":"Natural Science Foundation of Chengdu Medical College","award":["CYZYB20-14"],"award-info":[{"award-number":["CYZYB20-14"]}]},{"name":"China Baoyuan Research Fund","award":["CBYI202105"],"award-info":[{"award-number":["CBYI202105"]}]},{"name":"Sichuan Provincial Medical Youth Innovation Research","award":["Q21076"],"award-info":[{"award-number":["Q21076"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>As a promising positron emission tomography (PET) tracer, [68Ga]Ga-fibroblast activation protein inhibitor-04([68Ga]Ga-FAPI-04) performs better than 2-[18F]fluoro-2-deoxy-d-glucose ([18F]FDG) at diagnosing primary and metastatic lesions in patients with various types of cancer. We investigated the utility of [68Ga]Ga-FAPI-04 PET\/CT for the detection of primary and metastatic lesions in renal cell carcinoma (RCC). [18F]FDG PET\/CT were used for comparison.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Twenty-two patients with suspected RCC or recurrent RCC were enrolled in our study. Among these patients, 14 were newly diagnosed with RCC, 3 had recurrent RCC, and 5 were excluded from further analysis due to having benign renal tumours. Seventeen patients with RCC underwent [68Ga]Ga-FAPI-04 PET\/CT, and 6 of them also received [18F]FDG PET\/CT. The positive detection rates were calculated and compared with those in patients who underwent both scans.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Data from 17 patients with RCC (median age: 60.5\u2009years, interquartile range [IQR]: 54-70\u2009years) were evaluated. The positive detection rate of [68Ga]Ga-FAPI-04 PET\/CT for RCC was 64.7% (11\/17). Lymph node metastases (n\u2009=\u200944), lung metastasis (n\u2009=\u20091), and bone metastasis (n\u2009=\u20091) were detected. Six patients with RCC underwent [68Ga]Ga-FAPI-04 and [18F]FDG PET\/CT. [68Ga]Ga-FAPI-04 PET\/CT showed a higher positive detection rate than [18F]FDG PET\/CT in detecting RCC (83.3% [5\/6] vs. 50% [3\/6], P\u2009=\u20090.545). Additionally, [68Ga]Ga-FAPI-04 PET\/CT has higher SUVmax (3.20 [IQR: 2.91-5.80 vs. 2.71 [IQR: 2.13-3.10], P\u2009=\u20090.116) and tumour-to-background ratio (TBR) values (1.60 [IQR: 1.33-3.67] vs. 0.86 [0.48-1.21], P\u2009=\u20090.028) than [18F]FDG PET\/CT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These findings suggest that [68Ga]Ga-FAPI-04 PET\/CT has potential value in RCC diagnosis. Further studies are warranted to validate these results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Advances in knowledge<\/jats:title>\n                  <jats:p>Clinical utility of [68Ga]Ga-FAPI-04 in RCC remains unclear, and there are not many similar studies in the literature. We evaluated the role of [68Ga]Ga-FAPI-04 in diagnosing RCC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjr\/tqae025","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T02:05:05Z","timestamp":1706666705000},"page":"859-867","source":"Crossref","is-referenced-by-count":12,"title":["A pilot study of [68Ga]Ga-fibroblast activation protein inhibitor-04 PET\/CT in renal cell carcinoma"],"prefix":"10.1093","volume":"97","author":[{"given":"Chunmei","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University , Luzhou, Sichuan 646000, China"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University , Luzhou, Sichuan 646000, China"},{"name":"Institute of Nuclear Medicine, Southwest Medical University , Luzhou, Sichuan 646000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University , Luzhou, Sichuan 646000, China"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University , Luzhou, Sichuan 646000, China"},{"name":"Institute of Nuclear Medicine, Southwest Medical University , Luzhou, Sichuan 646000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haozhou","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Urology, Fushun People\u2019s Hospital , Zigong, Sichuan 643000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiao","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Second Affiliated Hospital of Chengdu Medical College (China National Nuclear Corporation 416 Hospital) , Chengdu, Sichuan 610000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University , Luzhou, Sichuan 646000, China"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University , Luzhou, Sichuan 646000, China"},{"name":"Institute of Nuclear Medicine, Southwest Medical University , Luzhou, Sichuan 646000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University , Luzhou, Sichuan 646000, China"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University , Luzhou, Sichuan 646000, China"},{"name":"Institute of Nuclear Medicine, Southwest Medical University , Luzhou, Sichuan 646000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University , Luzhou, Sichuan 646000, China"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University , Luzhou, Sichuan 646000, China"},{"name":"Institute of Nuclear Medicine, Southwest Medical University , Luzhou, Sichuan 646000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University , Luzhou, Sichuan 646000, China"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University , Luzhou, Sichuan 646000, China"},{"name":"Institute of Nuclear Medicine, Southwest Medical University , Luzhou, Sichuan 646000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University , Luzhou, Sichuan 646000, China"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University , Luzhou, Sichuan 646000, China"},{"name":"Institute of Nuclear Medicine, Southwest Medical University , Luzhou, Sichuan 646000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8204-1716","authenticated-orcid":false,"given":"Zhanwen","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University , Luzhou, Sichuan 646000, China"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University , Luzhou, Sichuan 646000, China"},{"name":"Institute of Nuclear Medicine, Southwest Medical University , Luzhou, Sichuan 646000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"issue":"4","key":"2024032822390692200_tqae025-B1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/01.mou.0000135078.04721.f5","article-title":"Renal cell carcinoma: etiology, incidence and epidemiology","volume":"14","author":"Murai","year":"2004","journal-title":"Curr Opin Urol"},{"issue":"1","key":"2024032822390692200_tqae025-B2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eururo.2014.04.029","article-title":"Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity","volume":"67","author":"Shuch","year":"2015","journal-title":"Eur Urol"},{"issue":"38","key":"2024032822390692200_tqae025-B3","doi-asserted-by":"crossref","first-page":"e1646","DOI":"10.1097\/MD.0000000000001646","article-title":"Prognostic significance of hypoxia-inducible factor expression in renal cell carcinoma: a PRISMA-compliant systematic review and meta-analysis","volume":"94","author":"Fan","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"2024032822390692200_tqae025-B4","first-page":"181","article-title":"Integrated FDG PET\/CT: utility and applications in clinical oncology","volume":"2","author":"Pinilla","year":"2008","journal-title":"Clin Med Oncol"},{"issue":"1","key":"2024032822390692200_tqae025-B5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/0256-4947.75771","article-title":"18F-FDG PET\/CT imaging in oncology","volume":"31","author":"Almuhaideb","year":"2011","journal-title":"Ann Saudi Med"},{"issue":"3","key":"2024032822390692200_tqae025-B6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/CCO.0000000000000518","article-title":"PET imaging in renal cancer","volume":"31","author":"Lindenberg","year":"2019","journal-title":"Curr Opin Oncol"},{"issue":"9","key":"2024032822390692200_tqae025-B7","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1007\/s00259-003-1211-4","article-title":"Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT","volume":"30","author":"Aide","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2024032822390692200_tqae025-B8","first-page":"201","article-title":"The Place of FDG PET\/CT in Renal Cell Carcinoma: value and limitations","volume":"6","author":"Liu","year":"2016","journal-title":"Front Oncol"},{"issue":"6","key":"2024032822390692200_tqae025-B9","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1007\/s00330-015-4026-3","article-title":"Clinical role of early dynamic FDG-PET\/CT for the evaluation of renal cell carcinoma","volume":"26","author":"Nakajima","year":"2016","journal-title":"Eur Radiol"},{"issue":"3","key":"2024032822390692200_tqae025-B10","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1102\/1470-7330.2012.0042","article-title":"Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET\/CT in renal cell carcinoma","volume":"12","author":"Wang","year":"2012","journal-title":"Cancer Imaging"},{"issue":"6","key":"2024032822390692200_tqae025-B11","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68)Ga-FAPI PET\/CT: Tracer Uptake in 28 Different Kinds of Cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"issue":"13","key":"2024032822390692200_tqae025-B12","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1007\/s00259-021-05475-0","article-title":"State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis","volume":"48","author":"Sollini","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"2024032822390692200_tqae025-B13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/ph14101023","article-title":"New Frontiers in cancer imaging and therapy based on radiolabeled fibroblast activation protein inhibitors: a rational review and current progress","volume":"14","author":"Imlimthan","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"8","key":"2024032822390692200_tqae025-B14","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","article-title":"Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer","volume":"47","author":"Chen","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2024032822390692200_tqae025-B15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/RLU.0000000000003454","article-title":"68Ga-fibroblast activation protein inhibitor, a promising radiopharmaceutical in PET\/CT to detect the primary and metastatic lesions of chromophobe renal cell carcinoma","volume":"46","author":"Pang","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"12","key":"2024032822390692200_tqae025-B16","doi-asserted-by":"crossref","first-page":"e758","DOI":"10.1097\/RLU.0000000000004374","article-title":"Superiority of 68Ga-FAPI-04 in delineation of soft tissue and liver metastases in chromophobe renal cell carcinoma for restaging","volume":"47","author":"Xie","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"5","key":"2024032822390692200_tqae025-B17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/RLU.0000000000004607","article-title":"68 Ga-FAPI-04 PET\/CT in a small sarcomatoid renal cell carcinoma with widespread metastases","volume":"48","author":"Dong","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"5","key":"2024032822390692200_tqae025-B18","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1097\/RLU.0000000000004587","article-title":"68 Ga-FAPI-04 PET\/CT and 18 F-FDG PET\/CT in metastatic papillary renal cell cancer","volume":"48","author":"Civan","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"3","key":"2024032822390692200_tqae025-B19","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s00259-023-06461-4","article-title":"The role of [(68) Ga]Ga-FAPI-04 PET\/CT in renal cell carcinoma: a preliminary study","volume":"51","author":"Civan","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"2024032822390692200_tqae025-B20","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","article-title":"Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy","volume":"49","author":"Zboralski","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"2024032822390692200_tqae025-B21","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2967\/jnumed.121.262426","article-title":"Correlation of (68)Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: interim analysis of a prospective translational exploratory study","volume":"63","author":"Mona","year":"2022","journal-title":"J Nucl Med"},{"key":"2024032822390692200_tqae025-B22","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.humpath.2016.03.009","article-title":"Fibroblast activation protein predicts prognosis in clear cell renal cell carcinoma","volume":"54","author":"L\u00f3pez","year":"2016","journal-title":"Hum Pathol"},{"issue":"12","key":"2024032822390692200_tqae025-B23","doi-asserted-by":"crossref","first-page":"e0169105","DOI":"10.1371\/journal.pone.0169105","article-title":"The expression of fibroblast activation protein in clear cell renal cell carcinomas is associated with synchronous lymph node metastases","volume":"11","author":"Errarte","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"2024032822390692200_tqae025-B24","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2967\/jnumed.122.264689","article-title":"Fibroblast-activation protein pet and histopathology in a single-center database of 324 patients and 21 tumor entities","volume":"64","author":"Hirmas","year":"2023","journal-title":"J Nucl Med"},{"issue":"7","key":"2024032822390692200_tqae025-B25","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2967\/jnumed.122.265245","article-title":"68)Ga-FAPI PET\/CT interobserver agreement on tumor assessment: an international multicenter prospective study","volume":"64","author":"Mei","year":"2023","journal-title":"J Nucl Med"},{"issue":"10","key":"2024032822390692200_tqae025-B26","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/RLU.0000000000004791","article-title":"Comparison of 18 F-FDG and 68 Ga-FAPI PET\/CT in a rare renal leiomyoma","volume":"48","author":"Liu","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"3","key":"2024032822390692200_tqae025-B27","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1097\/RLU.0000000000004022","article-title":"Increased 18F-ALF-NOTA-FAPI and 18F-FDG uptake in renal angiomyolipoma","volume":"47","author":"Guo","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"11","key":"2024032822390692200_tqae025-B28","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1097\/RLU.0000000000004297","article-title":"Lipid-poor renal angiomyolipoma mimicking renal cell carcinoma on 68 Ga-FAPI-04 PET\/CT","volume":"47","author":"Dong","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"3","key":"2024032822390692200_tqae025-B29","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00259-021-05554-2","article-title":"Fibroblast activation protein targeted therapy using [(177)Lu]FAPI-46 compared with [(225)Ac]FAPI-46 in a pancreatic cancer model","volume":"49","author":"Liu","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2024032822390692200_tqae025-B30","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2967\/jnumed.119.233122","article-title":"Theranostics targeting fibroblast activation protein in the tumor stroma: (64)Cu- and (225)Ac-labeled FAPI-04 in pancreatic cancer xenograft mouse models","volume":"61","author":"Watabe","year":"2020","journal-title":"J Nucl Med"},{"issue":"3","key":"2024032822390692200_tqae025-B31","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using (177)Lu-FAP-2286: first-in-humans results","volume":"63","author":"Baum","year":"2022","journal-title":"J Nucl Med"},{"issue":"19","key":"2024032822390692200_tqae025-B32","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1158\/1078-0432.CCR-22-1432","article-title":"Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities","volume":"28","author":"Fendler","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2024032822390692200_tqae025-B33","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1097\/RLU.0000000000003810","article-title":"Feasibility and therapeutic potential of 177Lu-fibroblast activation protein inhibitor-46 for patients with relapsed or refractory cancers: a preliminary study","volume":"46","author":"Assadi","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"1","key":"2024032822390692200_tqae025-B34","first-page":"65","article-title":"Novel fibroblast activation protein inhibitor-based targeted theranostics for radioiodine-refractory differentiated thyroid cancer patients: a pilot study","volume":"32","author":"Ballal","year":"2022","journal-title":"Thyroid"},{"issue":"12","key":"2024032822390692200_tqae025-B35","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1007\/s00259-020-04859-y","article-title":"Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers","volume":"47","author":"Syed","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"2024032822390692200_tqae025-B36","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1007\/s00259-023-06271-8","article-title":"F] AlF-NOTA-FAPI-04 PET\/CT can predict treatment response and survival in patients receiving chemotherapy for inoperable pancreatic ductal adenocarcinoma","volume":"50","author":"Zhu","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2024032822390692200_tqae025-B37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41416-022-01748-z","article-title":"Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by (68)Ga-FAPI-PET imaging","volume":"127","author":"Strating","year":"2022","journal-title":"Br J Cancer"},{"issue":"12","key":"2024032822390692200_tqae025-B38","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.2967\/jnumed.123.266079","article-title":"68)Ga-labeled fibroblast activation protein inhibitor PET\/CT for the early and late prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients: a prospective study","volume":"64","author":"Chen","year":"2023","journal-title":"J Nucl Med"},{"issue":"3","key":"2024032822390692200_tqae025-B39","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.radonc.2010.07.017","article-title":"Clinical evidence on PET-CT for radiation therapy planning in head and neck tumours","volume":"96","author":"Troost","year":"2010","journal-title":"Radiother Oncol"}],"container-title":["British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/advance-article-pdf\/doi\/10.1093\/bjr\/tqae025\/56679438\/tqae025.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/97\/1156\/859\/57116610\/tqae025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/97\/1156\/859\/57116610\/tqae025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T22:39:54Z","timestamp":1711665594000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/97\/1156\/859\/7593746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,30]]},"references-count":39,"journal-issue":{"issue":"1156","published-online":{"date-parts":[[2024,1,30]]},"published-print":{"date-parts":[[2024,3,28]]}},"URL":"https:\/\/doi.org\/10.1093\/bjr\/tqae025","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"value":"0007-1285","type":"print"},{"value":"1748-880X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4,1]]},"published":{"date-parts":[[2024,1,30]]}}}